Skip to main content
. 2022 Nov 17;30(2):383–396. doi: 10.1038/s41418-022-01090-0

Fig. 3. Inhibition of JAK2 attenuates lipid droplets accumulation in vitro.

Fig. 3

A BODIPY staining of lipid droplets in control and Fedratinib-treated WT and Arid2 KO hepatocytes. DMSO was used as a control. Scale bars, 90 μm. Blue signal, nuclei stained with Hoechst; Green signal, lipid droplets stained with BODIPY. B The inhibitory effect of Fedratinib on Jak2-Stat5 signaling in primary hepatocytes was confirmed by western blot. C BODIPY staining of lipid droplets in control and ARID2 knockdown HepG2 cells treated with DMSO or 5 μM Fedratinib for 16 h. Scale bars, 90 μm. D Inhibition of JAK2-STAT5 signaling by Fedratinib in HepG2 cells. E Primary hepatocytes isolated from WT and Arid2 LKO mice (n = 2 per group) were treated with either 10 μM Fedratinib or 5 μM Torin1 for 12 h. Lipid droplets in the hepatocytes were stained by BODIPY and quantified by Image J (3 images per mouse). Scale bars, 90 μm. All experiments were repeated 3 times independently. Data in E were analyzed with Mann-Whitney test and represented as the mean ± SEM. **p < 0.01, ns not significant.